Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE Jr, Malone DC, Trujillo JM, Gill J, Huse S, Li X, Zhou FL, Preblick R, Reid T. Wright EE Jr, et al. Among authors: gill j. J Manag Care Spec Pharm. 2022 Jun;28(6):592-603. doi: 10.18553/jmcp.2022.21436. Epub 2022 Mar 30. J Manag Care Spec Pharm. 2022. PMID: 35352995
Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.
Pettus J, Gill J, Paranjape S, Stewart J, Malla S, Edelman S, Bergenstal RM, Bode B. Pettus J, et al. Among authors: gill j. Diabetes Obes Metab. 2019 Aug;21(8):1906-1913. doi: 10.1111/dom.13751. Epub 2019 May 9. Diabetes Obes Metab. 2019. PMID: 30993855 Clinical Trial.
Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.
Meneghini L, Blonde L, Gill J, Dauchy A, Bacevicius A, Strong J, Bailey TS. Meneghini L, et al. Among authors: gill j. Diabetes Obes Metab. 2020 Nov;22(11):1995-2003. doi: 10.1111/dom.14116. Epub 2020 Jul 27. Diabetes Obes Metab. 2020. PMID: 32538550 Free PMC article. Clinical Trial.
A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
Meneghini LF, Sullivan SD, Oster G, Busch R, Cali AMG, Dauchy A, Gill J, Bailey TS. Meneghini LF, et al. Among authors: gill j. Diabetes Obes Metab. 2020 Nov;22(11):2004-2012. doi: 10.1111/dom.14152. Epub 2020 Sep 3. Diabetes Obes Metab. 2020. PMID: 32729217 Free PMC article. Clinical Trial.
3,245 results